AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05408377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MA group
Description: We will select Ashi points (the most obvious local pain over the breast), Tanzhong(CV17), bilateral Wuyi (ST15), Rugen (ST18), Tianzong(SI11), Geshu (BL17), Ganshu(BL18), Hegu(LI4), Sanyinjiao (SP6) and Taichong (LR3)in this trial.After insertion, all needles will be manually manipulated (equal manipulations of twirling, lifting, and thrusting)to achieve De qi sensation.
Study NCT05408377 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SA group
Description: The SA group will use a special needle in which the tip is blunt and the pedestal is opaque. There is an adhesive pad below the base to ensure that the whole pedestal can adhere to the points. Participants will receive superficial touch at bilateral sham GV8(Jinsuo), sham GV7(Zhongshu), sham GV6(Jizhong), sham GV5(Xuanshu), sham GV4(Mingmen), sham BL37(Yinmen), and sham BL57(Chengshan), the needles will touch the skin and not be inserted into the skin, then lift and twist each point evenly for 3 times, make the subject feel the similar sensation of deqi.
Study NCT06159361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance targeted exercises
Description: 6-week exercise program, 3 sessions per week (2 sessions in person, 1 session of home exercises. Participants will receive a booklet with information about the home exercises and will receive a text message reminder), each session will last 60 minutes.
Study NCT05236556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best practice advisory (BPA)
Description: For patients who are not on oral anticoagulation (AC) but have elevated stroke risk, the practice advisory will fire, which is to say it will be active in the providers workflow during outpatient encounters with a patient's primary care provider (PCP) or cardiology provider.
Study NCT06399666 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling
Study NCT05514548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-202
Description: INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.
Study NCT05514548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Matching size and number of tablets
Study NCT05988645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiWEndo System
Description: All colonoscopies will be performed with high-definition technology. The MiWEndo System will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System. The MiWEndo Analyzer will be managed by the assistant.~At the beginning of the extubation, the MiWEndo System will be turned on and the endoscopist will put music headphones on (blind to the results of MiWEndo).~In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time.
Study NCT06569212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol Dosing:~Metoprolol Injection (instructions: 5mg, once) Metoprolol Tab (25mg PO, q12 hours, timed to start 1hr after Metoprolol Injection, 6 doses) If unable to take PO medication, Metoprolol Injection (instructions, 5mg q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria
Study NCT06569212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Dosing:~Placebo Injection (instructions: 5mL NS, once) Placebo Tab (1 tab PO, q12 hours, timed to start 1hr after placebo injection, 6 doses) If unable to take PO medication, Placebo Injection (instructions, 5mL q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria
Study NCT04223115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitalized CBT with phone coaching
Description: Digitally delivered CBT intervention with weekly phone coaching
Study NCT04223115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation about depression
Description: Psychoeducational material about depression in a digitalized form
Study NCT06219525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Higher dose of enteral zinc
Description: Higher dose of zinc sulfate 10 mg/day; each 1 mL contains 10 mg of elemental zinc (osmolality 450 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.
Study NCT06219525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard dose of enteral zinc
Description: Standard dose of zinc sulfate 1 mg/day; each 1 mL contains 1 mg of elemental zinc (osmolality 45 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was discontinued at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.
Study NCT05795166 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study NCT05824650 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Individuals will be evaluated observationally in a 45-minute period in one day.
Study NCT06584903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature Ramp Protocol
Description: Following a 45 minute baseline in 37°C seated on a chair, the indoor temperature in the climate-controlled room increased from 37°C to 47°C at \~0.06°C/min (relative humidity \~26%) over 180 minutes.
Study NCT06584903 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Temperature Ramp Protocol
Description: Following a 45 minute baseline in 37°C seated on a chair, the indoor temperature in the climate-controlled room increased from 37°C to 47°C at \~0.06°C/min (relative humidity \~26%) over 180 minutes.
Study NCT06483230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intensive Visual Stimulation Device
Description: The therapist installs the patient in front of the device. First, patient puts the healthy side on the table and the therapist records several movements. The software of the device flips the video in order to create a mirrored image of the movement (pretty close to the mirror therapy approach). When all the movements are recorded, patient installs the affected side on the table and the screen is placed over the hand. Likewise, patient has the impression the hand is moving again. Thanks to this action observation principle, therapist can encourage the patient in trying to move again and increase brain plasticity.
Study NCT06483230 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Visual Stimulation Device
Description: The therapist installs the patient in front of the device. First, patient puts the healthy side on the table and the therapist records several movements. The software of the device flips the video in order to create a mirrored image of the movement (pretty close to the mirror therapy approach). When all the movements are recorded, patient installs the affected side on the table and the screen is placed over the hand. Likewise, patient has the impression the hand is moving again. Thanks to this action observation principle, therapist can encourage the patient in trying to move again and increase brain plasticity.
Study NCT05958082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational video
Description: The educational intervention will occur with a clinical research coordinator who will be trained to educate on germline testing in prostate cancer.
Study NCT05134935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defocus Incorporated Multiple Segment (DIMS) Spectacles
Description: 18 months of therapy.
Study NCT05134935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokerathology lenses (OKL)
Description: 18 months of therapy.
Study NCT04838171 — intervention group
Intervention type: OTHER
Intervention: White blood cell and blood collection
Description: Mononucleocytes will be collected via apheresis
Study NCT05014256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS Health System Outreach intervention
Description: STEPS Transplant Social Worker Education and Outreach, STEPS Transplant Coordinator Outreach
Study NCT04855552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight-loss Program Via Telehealth
Description: Investigators will use a manual based on the DPP, as adapted previously for the endometrial cancer population and now adapted for breast cancer survivors. Dr.Courtney McCuen-Wurst, has extensive experience in working with persons with overweight and obesity with medical comorbidities. She also has experience leading group interventions at our Center via telehealth. The content of the sessions addresses the domains associated with behavioral weight management including nutrition, exercise, stress and emotion management, and lifestyle modification strategies (to improve adherence to the diet and activity plan). Participants will monitor energy intake and physical activity daily to help them achieve recommended calorie and activity goals. Self-monitoring will be encouraged online with MyFitnessPal.com, which will be shared with the study staff to increase accountability and provide opportunity for feedback to participants.
Study NCT04855552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight-Loss Program Via Telehealth - Weight Measures
Description: Each participant will also be mailed a digital scale (Eat Smart) so they can weigh themselves each week and report their weight to the group leader; patients will be encouraged to take a picture of their weight on the scale after they step off (the number remains for 3-seconds) and send the picture to Dr. McCuen-Wurst. Participants will be encouraged to start with at least 1-minutes of moderately vigorous physical activity (e.g. brisk walking, swimming), at least five days per week, building up to at least 30-minutes per day (150-minutes per week) by week-6.
Study NCT04855552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Validated Surveys of Patient-Reported Outcomes
Description: The following surveys will be completed by participants pre- and post-intervention:~* COH-QOL Instrument - Breast Cancer Patient (QOL-BC)~* International Physical Activity Questionnaire (IPAQ) Short Form~* Patient Health Questionnaire (PHQ-9) (Depression)~* Acceptability of Intervention Measure~The following survey will be completed post-intervention~• Exit interview regarding acceptability of the program.~The following measurements/clinical tests results will be collected and compared pre- and post-intervention:~* Anthropometric measurements: height (self-report); weight (as measured on scale provided by study)~* Mammographic breast density estimated in annual clinical mammogram
Study NCT06651749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol injection
Description: hemodynamic changes of a high dose versus low dose propofol during induction of anesthesia.
Study NCT05099770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Participants will have a kidney biopsy followed 14 weeks later with a REACT injection into the biopsied kidney, then, another 12 weeks (+28 days) later a REACT injection into their contralateral kidney.
Study NCT05099770 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Participants will have 2 sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The second sham procedure will occur 12 weeks (+28 days) after the first sham procedure.
Study NCT06599827 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: moderately hypofractionated radiotherapy
Description: 35 Gy in 10 fractions to mesorectal and metastatic lymph nodes, and 30 Gy in 10 fractions to pelvic lymphatic drainage area, weekly over 5 days at 3-3.5 Gy/day.
Study NCT06599827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: CapeOx-Capecitabine 1000 mg/m² orally twice daily (days 1-14, every 21 days) + Oxaliplatin 130 mg/m² IV (day 1, every 21 days).
Study NCT06599827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunotherapy
Description: Serplulimab 300 mg IV infusion on day 1 every 21 days.
Study NCT06599827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) surgery
Description: Total mesorectal excision (TME) surgery assessment post 3 cycles of chemotherapy and immunotherapy; eligible patients undergo TME surgery.
Study NCT06597851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thermodilution based assessment of coronary microcirculation
Description: Coronary microvascular assessment with the derivation of CFR, IMR and MRR will be performed using a standard pressure/thermodilution guidewire.
Study NCT06597851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-euglycemic Clamp test
Description: Infusion of insulin and glucose adjusting rate of glucose infusion to maintaine plasma glucose around 90 mg/dL by monitoring plasma glucose levels every 5-10 minutes
Study NCT06612320 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire about acceptance
Description: Questionnaire about acceptance
Study NCT06612320 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire about refusal
Description: Questionnaire about refusal
Study NCT06595082 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4-week lupins in brine consumption
Description: Volunteers were asked to consume lupins in brine for 4 weeks.
Study NCT06595082 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4-week lupins in brine consumption and dietary suggestion
Description: Volunteers were asked to consume lupins in brine for 4 weeks and refrain to two servings per week of meat or processed meat or cheese.
Study NCT06593171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring program
Description: This three-session mentoring program is based on experiential learning and has been validated and adapted to our country. The mentors, professionals with lived experience in mental health, will provide knowledge and experiences to the students through direct contact sessions in the classroom, focusing especially on the processes of recovery and self-determination.
Study NCT06593171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (placebo) group
Description: This group will not receive any intervention. However, they will be invited to participate in stigma education after the study is completed.
Study NCT06704282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Mindfulness Meditation Program
Description: A 15-minute guided mindfulness meditation session conducted in a virtual reality environment to enhance stress reduction and mindfulness.
Study NCT06705010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of new pulse sequence package SIGNATURES2023 to healthy controls
Description: One or more novel or further optimized non CE-marked pulse MRSI sequence is/are applied to 100 healthy subjects to determined reference metabolite maps of the whole brain
Study NCT06705010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of new pulse sequence package SIGNATURES2023 to 4 groups of patients (pilot)
Description: One or more novel or further optimized non CE-marked pulse MRSI sequence is/are applied to 4 time 10 patients with AD, MCI, DM and HGCS to determine metabolite maps of the whole brain.
Study NCT06706024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise
Description: Patients Under Hemodialysis
Study NCT06705699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urethral mobilisation
Description: Involves mobilizing the urethral tube proximally and advancing it distally to the glans. The urethra is repositioned and sutured at the neomeatal position.
Study NCT06705699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mathieu
Description: Utilizes a perimeatal-based flap, which is flipped up to create the neourethra.
Study NCT06705036 — intervention group
Intervention type: OTHER
Intervention: surgery
Description: Samples were obtained from patients by surgical excision and matched into groups
Study NCT06705387 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Subcutaneous injection of 300mg per week for 16 weeks.
Study NCT06705387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Metered dose swallowed topical corticosteroid, given 1760mcg per day for 16 weeks.
Study NCT06704243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: The intervention will be a monthly online AYA peer support group (1 hour) that will run for six months via Microsoft Teams.~In an effort to evaluate a patient-driven real-world intervention, the support group has been designed with the following features: 1) participants will be asked to commit for a six month period, but are able to miss sessions if necessary; and, 2) each session will be facilitated by a Nurse Practitioner and Social Worker from the Allo-HSCT program, but the topics of discussion will be determined by the AYA participants present at each session. Participants in the group will then be invited to share their thoughts and experiences about these topics, with as much information as they feel comfortable.
Study NCT04839705 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: WEB
Description: Device: WEB The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~Other Names:~• WEB Aneurysm Embolization Device
Study NCT03727815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Pain Management Arm
Description: Mindfulness Pain Management intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the pain management mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
Study NCT03727815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Self Esteem Arm
Description: Mindfulness Self Esteem intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the self esteem mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
Study NCT04875884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified MRI
Description: A technical modification to the standard MRI which only affects radiofrequency pulse polarization attempting to optimize the image quality. All other factors, including pulse sequence parameters, and patient and coil positioning is similar to that of the standard MRI.
Study NCT06349798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: 20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a similer bolus every 4 h for 24 h (6 injections in total) + continuous intravenous infusion of placebo (2 mL/h saline)
Study NCT06349798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: 20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a bolus of placebo every 4 h for 24 h (6 injections in total) + continuous infusion of 100 mg nefopam over 24 h (in 48 mL saline, 2 mL/h)
Study NCT06349798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: 50 ml of saline, during a 30 min infusion, before end of procedure, followed by a bolus of placebo every 4 hours for 24 hours (6 injections in all) + continuous infusion of placebo (2 mL/h of physiological saline)
Study NCT05736874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.